Clinical trial · Interventional
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cediranib | Drug | Cediranib | ALIAS |
| Lomustine Chemotherapy | Drug | — | UNRESOLVED |
| Placebo Cediranib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cediranib 30mg
- description
- Cediranib 30mg
- interventionNames
- Drug: Cediranib
- type
- OTHER
- label
- Cediranib 20mg + lomustine
- description
- Cediranib 20mg + lomustine
- interventionNames
- Drug: Cediranib
- Drug: Lomustine Chemotherapy
- type
- ACTIVE_COMPARATOR
- label
- Lomustine and Placebo Cediranib
- description
- Lomustine and Placebo Cediranib
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmation of recurrent glioblastoma * Life expectancy ≥ 12 weeks * Received only one prior systemic chemotherapy regimen and this regimen must contain temozolomide Exclusion Criteria: * Patients on enzyme-inducing anti-epileptic drugs within 3 weeks prior to randomisation * Poorly controlled hypertension * Previous anti-angiogenesis (eg bevacizumab, sorafenib, sunitinib) therapy
References
Publications (1)
- DERIVEDBatchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10;31(26):3212-8. doi: 10.1200/JCO.2012.47.2464. Epub 2013 Aug 12. PMID 23940216